Dr Reddy's Laboratories (RDY) is disputing reports it plans to cut a significant portion of its workforce, with the India-based drug maker telling Indian regulators on Monday that a Business Standard report published overnight was "factually incorrect."
In a letter sent Monday to the National Stock Exchange of India, Kumar Singh, Dr Reddy's compliance officer, said it "categorically" denies the reported job actions, adding there is nothing happening at the company at this time that would typically trigger a disclosure.
The Business Standard report, citing multiple individuals with knowledge of the matter, said Dr Reddy recently began a "significant downsizing initiative" expected to reduce its workforce costs by 25%.
Dr Reddy shares recently was fractionally lower in US late-morning trading.
Price: 13.20, Change: -0.03, Percent Change: -0.19
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。